Pentixapharm develops first-in-class radiopharmaceutical approaches to improve patient life. The company has two drug candidates ready for Phase III studies, including a CXCR4 compound with extensive scientific validation. They focus on advancing diagnostic and therapeutic radiopharmaceuticals through clinical development.
Funding
$16.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers express the CXCR4 receptor, which contributes to tumor growth, metastasis, and resistance to conventional therapies. Traditional cancer treatments often lack the precision to selectively target these CXCR4-expressing cancer cells, leading to off-target effects and suboptimal outcomes.
Solution
Pentixapharm develops targeted radiopharmaceuticals, specifically the PentixaFor and PentixaTher pair, designed to selectively bind to the CXCR4 receptor on cancer cells. PentixaFor is used for diagnostic imaging to identify and quantify CXCR4 expression within tumors. PentixaTher then delivers targeted radiotherapy, directly irradiating CXCR4-positive cancer cells while minimizing damage to surrounding healthy tissue. This theranostic approach aims to improve treatment efficacy and reduce side effects in patients with cancers expressing the CXCR4 receptor.
Target Audience
The primary target audience includes patients with cancers expressing the CXCR4 receptor, particularly those with acute myeloid leukemia and acute lymphoblastic leukemia, as well as oncologists and nuclear medicine specialists seeking more precise cancer therapies.
Features
- PentixaFor: A diagnostic radiopharmaceutical for PET imaging of CXCR4 expression in tumors.
- PentixaTher: A therapeutic radiopharmaceutical that delivers targeted radiation to CXCR4-positive cancer cells.
- Targets the CXCR4 receptor, which is overexpressed in various cancers, including acute myeloid leukemia and acute lymphoblastic leukemia.
- Aims to enhance the precision of targeted radiotherapy.